 Rocio Pereira
Concepts (173)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Adiponectin | 5 | 2016 | 243 | 1.300 |
Why?
| | Health Promotion | 3 | 2025 | 748 | 0.960 |
Why?
| | Community Health Workers | 1 | 2025 | 76 | 0.880 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2025 | 2524 | 0.850 |
Why?
| | Public Policy | 1 | 2023 | 75 | 0.800 |
Why?
| | Prejudice | 1 | 2023 | 60 | 0.800 |
Why?
| | Minority Groups | 2 | 2024 | 277 | 0.770 |
Why?
| | Insulin Resistance | 7 | 2017 | 1218 | 0.760 |
Why?
| | Blood Glucose Self-Monitoring | 2 | 2023 | 704 | 0.670 |
Why?
| | Blood Glucose | 5 | 2023 | 2273 | 0.530 |
Why?
| | Adipocytes | 3 | 2016 | 220 | 0.490 |
Why?
| | Attitude of Health Personnel | 1 | 2024 | 1175 | 0.480 |
Why?
| | Weight Reduction Programs | 1 | 2017 | 117 | 0.470 |
Why?
| | Adiposity | 3 | 2015 | 518 | 0.470 |
Why?
| | Phosphatidylinositol 3-Kinases | 2 | 2008 | 368 | 0.450 |
Why?
| | Mexican Americans | 1 | 2015 | 112 | 0.440 |
Why?
| | Renal Insufficiency, Chronic | 1 | 2021 | 622 | 0.430 |
Why?
| | Weight Loss | 5 | 2025 | 790 | 0.390 |
Why?
| | Diabetes Mellitus | 2 | 2022 | 1072 | 0.380 |
Why?
| | Medicare | 1 | 2017 | 806 | 0.350 |
Why?
| | Postmenopause | 3 | 2017 | 369 | 0.340 |
Why?
| | Racism | 2 | 2024 | 139 | 0.340 |
Why?
| | Diet | 1 | 2015 | 1269 | 0.280 |
Why?
| | Thiazolidinediones | 1 | 2008 | 137 | 0.270 |
Why?
| | Adult | 17 | 2026 | 39134 | 0.270 |
Why?
| | Middle Aged | 18 | 2026 | 34487 | 0.260 |
Why?
| | Subcutaneous Fat | 2 | 2017 | 81 | 0.250 |
Why?
| | Humans | 29 | 2026 | 140898 | 0.240 |
Why?
| | Narration | 1 | 2026 | 68 | 0.220 |
Why?
| | Inpatients | 2 | 2023 | 512 | 0.220 |
Why?
| | Colorado | 4 | 2026 | 4597 | 0.220 |
Why?
| | United States | 6 | 2023 | 15195 | 0.210 |
Why?
| | Supreme Court Decisions | 1 | 2023 | 11 | 0.210 |
Why?
| | Community Health Centers | 1 | 2024 | 63 | 0.210 |
Why?
| | Reminder Systems | 1 | 2026 | 174 | 0.210 |
Why?
| | Text Messaging | 2 | 2016 | 179 | 0.210 |
Why?
| | Estradiol | 2 | 2017 | 523 | 0.200 |
Why?
| | Prediabetic State | 2 | 2016 | 251 | 0.200 |
Why?
| | Cultural Diversity | 1 | 2024 | 84 | 0.200 |
Why?
| | Food Assistance | 1 | 2023 | 33 | 0.190 |
Why?
| | Female | 21 | 2026 | 75540 | 0.190 |
Why?
| | Safety-net Providers | 1 | 2023 | 124 | 0.180 |
Why?
| | Body Mass Index | 5 | 2025 | 2374 | 0.180 |
Why?
| | Male | 16 | 2026 | 69893 | 0.180 |
Why?
| | Program Evaluation | 1 | 2025 | 919 | 0.170 |
Why?
| | Influenza Vaccines | 1 | 2026 | 551 | 0.170 |
Why?
| | Interviews as Topic | 1 | 2024 | 841 | 0.160 |
Why?
| | Estrogen Receptor beta | 2 | 2017 | 41 | 0.160 |
Why?
| | Postpartum Period | 1 | 2023 | 343 | 0.160 |
Why?
| | Hypoglycemic Agents | 2 | 2012 | 1368 | 0.160 |
Why?
| | Obesity | 3 | 2023 | 3000 | 0.160 |
Why?
| | Influenza, Human | 1 | 2026 | 625 | 0.150 |
Why?
| | Vaccination | 2 | 2026 | 1467 | 0.150 |
Why?
| | Estrogen Receptor alpha | 2 | 2017 | 144 | 0.150 |
Why?
| | Feasibility Studies | 1 | 2023 | 1022 | 0.150 |
Why?
| | Medicaid | 1 | 2023 | 446 | 0.150 |
Why?
| | Patient Care Team | 1 | 2024 | 664 | 0.140 |
Why?
| | Cost of Illness | 1 | 2021 | 310 | 0.140 |
Why?
| | Overweight | 1 | 2023 | 587 | 0.140 |
Why?
| | Dietary Fats | 2 | 2018 | 299 | 0.140 |
Why?
| | Insulin | 4 | 2012 | 2458 | 0.140 |
Why?
| | Delivery of Health Care | 2 | 2024 | 949 | 0.140 |
Why?
| | Sleep Wake Disorders | 1 | 2021 | 304 | 0.130 |
Why?
| | Health Personnel | 1 | 2024 | 724 | 0.130 |
Why?
| | Caregivers | 1 | 2026 | 940 | 0.130 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2017 | 41 | 0.130 |
Why?
| | 3T3-L1 Cells | 2 | 2008 | 36 | 0.130 |
Why?
| | Body Fat Distribution | 1 | 2017 | 47 | 0.130 |
Why?
| | Critical Illness | 1 | 2023 | 837 | 0.130 |
Why?
| | Age Factors | 2 | 2017 | 3278 | 0.130 |
Why?
| | Pericardium | 1 | 2017 | 58 | 0.130 |
Why?
| | Cross-Sectional Studies | 4 | 2021 | 5645 | 0.130 |
Why?
| | Cyclic AMP-Dependent Protein Kinases | 1 | 2017 | 129 | 0.130 |
Why?
| | Exercise | 2 | 2025 | 2108 | 0.120 |
Why?
| | Qualitative Research | 1 | 2024 | 1525 | 0.120 |
Why?
| | Human Development | 1 | 2016 | 22 | 0.120 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2017 | 97 | 0.120 |
Why?
| | Diabetes Mellitus, Type 1 | 2 | 2017 | 3788 | 0.120 |
Why?
| | Organ Specificity | 1 | 2016 | 311 | 0.120 |
Why?
| | Diet Surveys | 1 | 2015 | 91 | 0.120 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3336 | 0.120 |
Why?
| | Insurance Coverage | 1 | 2017 | 239 | 0.110 |
Why?
| | Puberty | 1 | 2016 | 152 | 0.110 |
Why?
| | Healthy Volunteers | 1 | 2015 | 214 | 0.110 |
Why?
| | Adipose Tissue | 2 | 2017 | 645 | 0.110 |
Why?
| | Weight Gain | 1 | 2018 | 537 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2017 | 411 | 0.110 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2015 | 142 | 0.110 |
Why?
| | Sex Factors | 2 | 2017 | 2051 | 0.110 |
Why?
| | Cohort Studies | 2 | 2017 | 5789 | 0.100 |
Why?
| | Language | 1 | 2017 | 309 | 0.100 |
Why?
| | Energy Metabolism | 2 | 2018 | 930 | 0.100 |
Why?
| | Socioeconomic Factors | 2 | 2017 | 1310 | 0.100 |
Why?
| | Pilot Projects | 3 | 2026 | 1815 | 0.090 |
Why?
| | Stem Cells | 1 | 2016 | 603 | 0.090 |
Why?
| | Signal Transduction | 1 | 2005 | 5148 | 0.090 |
Why?
| | Abdominal Fat | 1 | 2012 | 41 | 0.090 |
Why?
| | Logistic Models | 1 | 2017 | 2088 | 0.090 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2012 | 158 | 0.090 |
Why?
| | Molecular Weight | 1 | 2012 | 327 | 0.090 |
Why?
| | Glucose Clamp Technique | 1 | 2012 | 197 | 0.090 |
Why?
| | Self Report | 1 | 2015 | 858 | 0.090 |
Why?
| | Vascular Stiffness | 1 | 2015 | 449 | 0.090 |
Why?
| | Patient Admission | 1 | 2012 | 203 | 0.080 |
Why?
| | Cell Differentiation | 1 | 2016 | 1999 | 0.070 |
Why?
| | Insulin Antagonists | 1 | 2008 | 6 | 0.070 |
Why?
| | Androstadienes | 1 | 2008 | 74 | 0.070 |
Why?
| | Retrospective Studies | 3 | 2023 | 16315 | 0.070 |
Why?
| | Young Adult | 4 | 2023 | 13646 | 0.070 |
Why?
| | Muscle, Skeletal | 1 | 2017 | 1750 | 0.060 |
Why?
| | Enzyme Activation | 1 | 2008 | 801 | 0.060 |
Why?
| | Hypertension | 1 | 2015 | 1251 | 0.060 |
Why?
| | Sex Characteristics | 1 | 2012 | 785 | 0.060 |
Why?
| | Blotting, Western | 1 | 2008 | 1231 | 0.060 |
Why?
| | Aged | 5 | 2017 | 24666 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 150 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 183 | 0.060 |
Why?
| | Diet, Reducing | 1 | 2005 | 90 | 0.060 |
Why?
| | Biomarkers | 1 | 2015 | 4175 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2008 | 2056 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2016 | 2822 | 0.050 |
Why?
| | Cell Line | 1 | 2008 | 2879 | 0.050 |
Why?
| | Cystic Fibrosis | 1 | 2012 | 1129 | 0.050 |
Why?
| | Phobic Disorders | 1 | 2022 | 36 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 2008 | 1485 | 0.050 |
Why?
| | Policy | 1 | 2022 | 145 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4199 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2004 | 431 | 0.040 |
Why?
| | Mice | 2 | 2008 | 18057 | 0.040 |
Why?
| | Adolescent | 2 | 2016 | 22027 | 0.040 |
Why?
| | Poverty | 1 | 2023 | 527 | 0.040 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 19 | 0.030 |
Why?
| | Health Behavior | 1 | 2023 | 783 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2017 | 5194 | 0.030 |
Why?
| | Placebos | 1 | 2017 | 195 | 0.030 |
Why?
| | Cell Size | 1 | 2016 | 89 | 0.030 |
Why?
| | Intra-Abdominal Fat | 1 | 2017 | 89 | 0.030 |
Why?
| | Adipogenesis | 1 | 2016 | 56 | 0.030 |
Why?
| | Hospitalization | 2 | 2022 | 2261 | 0.030 |
Why?
| | Cell Phone | 1 | 2016 | 82 | 0.030 |
Why?
| | Healthcare Disparities | 1 | 2022 | 671 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2017 | 577 | 0.030 |
Why?
| | Animals | 2 | 2008 | 37579 | 0.030 |
Why?
| | Sleep | 1 | 2021 | 879 | 0.030 |
Why?
| | Treatment Outcome | 3 | 2016 | 11125 | 0.030 |
Why?
| | Likelihood Functions | 1 | 2012 | 145 | 0.020 |
Why?
| | Infant | 1 | 2026 | 9790 | 0.020 |
Why?
| | Texas | 1 | 2012 | 262 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 1968 | 0.020 |
Why?
| | Double-Blind Method | 1 | 2015 | 1978 | 0.020 |
Why?
| | Child, Preschool | 1 | 2026 | 11462 | 0.020 |
Why?
| | Enteral Nutrition | 1 | 2012 | 201 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1745 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2017 | 3578 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2016 | 2497 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2021 | 5931 | 0.020 |
Why?
| | Insulin Infusion Systems | 1 | 2012 | 466 | 0.020 |
Why?
| | Apoptosis | 1 | 2016 | 2571 | 0.020 |
Why?
| | Lipids | 1 | 2012 | 689 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2016 | 2604 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1862 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6944 | 0.020 |
Why?
| | Basal Metabolism | 1 | 2005 | 63 | 0.010 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2012 | 2128 | 0.010 |
Why?
| | Dietary Carbohydrates | 1 | 2005 | 152 | 0.010 |
Why?
| | Hospitals, Urban | 1 | 2004 | 137 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3172 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 7749 | 0.010 |
Why?
| | Fasting | 1 | 2005 | 283 | 0.010 |
Why?
| | Energy Intake | 1 | 2005 | 510 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2012 | 2760 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 481 | 0.010 |
Why?
| | Child | 1 | 2016 | 22313 | 0.010 |
Why?
|
|
Pereira's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|